Common Asthma Drug Target May Unlock Stalled Cancer Immunotherapy
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
Summary
Cancer tumors often hijack the body's immune system by generating immunosuppressive neutrophils that shield them from attack. Researchers at Northwestern University found that a receptor called CysLTR1 — already known in asthma biology — plays a key role in driving this process. When CysLTR1 was blocked genetically or with existing approved drugs, tumor growth slowed, immunosuppressive neutrophils were reprogrammed into cancer-fighting cells, and mice that previously did not respond to anti-PD1 immunotherapy began to respond. This suggests that repurposing already-available CysLTR1 inhibitors could help patients whose cancers resist checkpoint immunotherapy, one of the biggest challenges in modern oncology.
Detailed Summary
One of the greatest obstacles in cancer immunotherapy is resistance — many tumors simply stop responding to checkpoint blockers like anti-PD1 drugs. Understanding why requires looking at how tumors manipulate the immune environment around them, particularly through a process called emergency myelopoiesis.
Researchers from Northwestern University's Lurie Cancer Center investigated how tumors exploit emergency myelopoiesis to generate large numbers of immunosuppressive neutrophils, also called polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). These cells are potent suppressors of antitumor immunity and major contributors to checkpoint therapy failure. The team identified that a receptor called cysteinyl leukotriene receptor 1 (CysLTR1), regulated by the signaling protein STAT3, is a critical driver of this tumor-promoting process.
Using both genetic deletion and pharmacological inhibition of CysLTR1 in mouse tumor models, the researchers showed that blocking this receptor significantly reduced tumor growth. The mechanism involved a transcriptomic rewiring of how granulocytes (a white blood cell type) develop, shifting neutrophil differentiation from an immunosuppressive to an antitumor phenotype. Two specific transcription factors — MXD1 and NFE2 — were found to govern myeloid progenitor commitment during this reprogramming process.
Critically, combining CysLTR1 antagonists with anti-PD1 therapy overcame resistance across multiple mouse tumor models, suggesting a powerful synergistic strategy. Since CysLTR1 antagonists are already clinically approved for conditions like asthma, the path to clinical translation may be faster than developing entirely new compounds.
Caveats include that all experimental data come from mouse models, and the full abstract does not detail which specific CysLTR1 antagonists were tested. Human trials will be needed to confirm efficacy, safety, and optimal dosing in cancer patients. The summary is based on the abstract only.
Key Findings
- CysLTR1, driven by STAT3 signaling, sustains tumor-promoting emergency myelopoiesis in cancer.
- Blocking CysLTR1 genetically or pharmacologically reduced tumor growth and boosted antitumor immunity.
- Neutrophils were reprogrammed from immunosuppressive to antitumor phenotype via MXD1 and NFE2 transcription factors.
- CysLTR1 inhibitors overcame anti-PD1 resistance in multiple mouse tumor models.
- Clinically approved CysLTR1 antagonists (already used in asthma) could be rapidly repurposed for cancer.
Methodology
The study used genetic ablation and pharmacological inhibition of CysLTR1 across multiple mouse tumor models. Transcriptomic analysis revealed mechanisms of neutrophil reprogramming. Combination experiments tested CysLTR1 antagonists alongside anti-PD1 checkpoint therapy.
Study Limitations
All data are derived from mouse tumor models; human clinical validation is still needed. The specific CysLTR1 antagonists tested and their doses are not detailed in the abstract. This summary is based on the abstract only, as the full text is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.